| Natera: The Clues In Q1 Earnings |
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue. |
seekingalpha.com |
2025-05-16 12:41:18 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-09 01:30:36 |
Czytaj oryginał (ang.) |
| Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript |
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript |
seekingalpha.com |
2025-05-09 00:58:05 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates |
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago. |
zacks.com |
2025-05-08 23:00:48 |
Czytaj oryginał (ang.) |
| Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712. |
businesswire.com |
2025-05-08 14:30:00 |
Czytaj oryginał (ang.) |
| Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the to. |
businesswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera's personalized molecular residual disease (MRD) test, in patients with soft tissue and bone sarcomas. Results of the study (Utilizing Circulating Tumor DNA to Monitor Sarcoma Treatment and Recurrence) were presented at the 2025 Society of Surgical Oncology. |
businesswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-der. |
businesswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| Baron Health Care Fund Q1 2025 Top Net Purchases And Sales |
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. |
seekingalpha.com |
2025-04-29 15:45:00 |
Czytaj oryginał (ang.) |
| Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States. This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In this clinical validation study of more than 3,000 sam. |
businesswire.com |
2025-04-24 11:00:00 |
Czytaj oryginał (ang.) |
| Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL. Highlights from AACR include: An oral presentation titled “Large-scale Genomic Profiling of Colorectal Cancer” from an exploratory analysis examining the characteristics of the mutational landscape of C. |
businesswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| 27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks |
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual returns of 30%. |
fool.com |
2025-04-07 11:00:00 |
Czytaj oryginał (ang.) |
| DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as. |
businesswire.com |
2025-03-25 09:00:00 |
Czytaj oryginał (ang.) |
| Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings |
Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000. |
fool.com |
2025-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time |
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time |
seekingalpha.com |
2025-03-17 13:52:59 |
Czytaj oryginał (ang.) |
| Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial is supported by funding from the French Ministry of Health through the Hospital Clinical Research Program (PHRC) and. |
businesswire.com |
2025-03-10 10:00:00 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-03-07 12:30:53 |
Czytaj oryginał (ang.) |
| Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript |
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-28 02:23:05 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates |
Natera (NTRA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.64 per share a year ago. |
zacks.com |
2025-02-27 21:25:34 |
Czytaj oryginał (ang.) |
| Natera Reports Fourth Quarter and Full Year 2024 Financial Results |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quart. |
businesswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with resectable or unresectable disease in the surveillance setting. It expands upon preexistin. |
businesswire.com |
2025-02-25 08:00:00 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Recently Broke Out Above the 20-Day Moving Average |
From a technical perspective, Natera (NTRA) is looking like an interesting pick, as it just reached a key level of support. NTRA recently overtook the 20-day moving average, and this suggests a short-term bullish trend. |
zacks.com |
2025-02-17 12:35:24 |
Czytaj oryginał (ang.) |
| NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for colon cancer, rectal cancer, and merkel cell carcinoma (MCC). In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in. |
businesswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| Billionaire Stanley Druckenmiller says the AI boom could get much bigger – These are the stocks he owns |
Stanley Druckenmiller is one of those legendary investors who are worth listening to and learning from. |
247wallst.com |
2025-02-04 12:58:13 |
Czytaj oryginał (ang.) |
| Natera Announces National Commercial Coverage for its Fetal RhD NIPT |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United States. Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygou. |
businesswire.com |
2025-02-03 09:00:00 |
Czytaj oryginał (ang.) |
| Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer |
AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA. This first-of-its-kind study evaluated whether Signatera-positive patients benefit from an. |
businesswire.com |
2025-01-25 12:05:00 |
Czytaj oryginał (ang.) |
| Natera to Present New Data at the 2025 ASCO GI Symposium |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23 – 25, 2025 in San Francisco, CA. BESPOKE CRC Study New data will be presented in an oral presentation on Jan. 25 from BESPOKE CRC, a multicenter, prospective, obse. |
businesswire.com |
2025-01-21 20:05:00 |
Czytaj oryginał (ang.) |
| Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top healthcare technology CEOs for 2024, as determined by Healthcare Technology Report. Chapman was also named “BioTechnology Innovator of the Year” in 2024, in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough. These recognitions highlight Chapman's leadership at Nate. |
businesswire.com |
2025-01-17 11:00:00 |
Czytaj oryginał (ang.) |
| Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following: Total revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter of 2023, an increase of approximately 52%. Total revenues of approximately $1.7 billion in the full year 2024 compared t. |
businesswire.com |
2025-01-12 21:20:00 |
Czytaj oryginał (ang.) |
| Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings |
Decades away from his star-making turn at George Soros' Quantum Group of Funds, high-profile investor Stanley Druckenmiller stays well active in the stock-picking game with his Duquesne Family Office investment vehicle. |
fool.com |
2025-01-09 10:15:00 |
Czytaj oryginał (ang.) |
| Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, Jan. 15, 2025 at 9:00 a.m. PT (12:00 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera website at investo. |
businesswire.com |
2025-01-07 11:00:00 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services + |
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering diverse investment opportunities and encouraging discussion among investors. Ready Capital Corporation's new senior notes offer a 9% yield but are seen to face risks due to recent dividend cuts and negative earnings-to-debt ratios. Alex Pitti sees AVITA Medical showing strong growth potential with new product launches and increased market opportunities, making it a compelling long-term investment. |
seekingalpha.com |
2025-01-03 16:00:02 |
Czytaj oryginał (ang.) |
| Natera: Poised For A Great Future But I'd Wait For A Pullback |
Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. The company's competitive landscape is intense, with rivals like Guardant Health and Quest Diagnostics, and ongoing litigation posing potential risks. Natera's revenue growth is driven by its oncology segment, particularly the Signatera test, but future growth may moderate as it nears its TAM. |
seekingalpha.com |
2024-12-31 07:50:00 |
Czytaj oryginał (ang.) |
| Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings |
Billionaire Stanley Druckenmiller might not be a household name like Warren Buffett, but he's one of the best investors of all time. |
fool.com |
2024-12-21 13:00:00 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy? |
After reaching an important support level, Natera (NTRA) could be a good stock pick from a technical perspective. NTRA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. |
zacks.com |
2024-12-17 12:35:38 |
Czytaj oryginał (ang.) |
| Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests. On December 10, 2024, the District Court for the Middle District of North Carolina (“The District Court”) granted Natera's request to include an additional patent in its ongoing lawsuit against NeoGenomics. Natera's amended complaint now includes U.S. Paten. |
businesswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company's clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT). Natera's study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 65. |
businesswire.com |
2024-12-02 10:00:00 |
Czytaj oryginał (ang.) |
| Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients in the surveillance setting. SLT patients make up ~20% of all U.S. lung transplants1. These patients are at an increase. |
businesswire.com |
2024-11-27 11:00:00 |
Czytaj oryginał (ang.) |
| Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts. “We are proud to share this new data on Signatera at SABCS that underscores our commitment to generating evidence on the clinical utility of Signatera for patient. |
businesswire.com |
2024-11-25 21:57:00 |
Czytaj oryginał (ang.) |
| Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™ |
Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO ALTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District Court for the Northern District of California (the "Court") unanimously found in favor of Guardant Health on all of its claims from its May 2021 lawsuit against Natera, Inc. (Nasdaq: NTRA) ("Natera") for false advertising and unfair competition. |
prnewswire.com |
2024-11-25 19:09:00 |
Czytaj oryginał (ang.) |
| Natera Issues Statement on Guardant Health Litigation |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement: In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant's Reveal test. Today, a jury issued a decision in Guardant's favor. We disagree with this decision and will ask the Court to overturn it. The jury was asked to evaluate comparati. |
businesswire.com |
2024-11-25 17:51:00 |
Czytaj oryginał (ang.) |
| Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. Thes. |
businesswire.com |
2024-11-21 19:31:00 |
Czytaj oryginał (ang.) |
| Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings |
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings |
fool.com |
2024-11-21 10:30:00 |
Czytaj oryginał (ang.) |
| Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript |
Natera, Inc. (NASDAQ:NTRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 AM ET Company Participants Mike Brophy - CFO Steve Chapman - CEO Alexey Aleshin - GM Oncology, CMO Conference Call Participants Puneet Souda - Leerink Partners Daniel Brennan - TD Cowen Tejas Savant - Morgan Stanley Rachel Vatnsdal - JP Morgan Douglas Schenkel - Wolfe Research Matthew Sykes - Goldman Sachs Tycho Peterson - Jefferies Operator Welcome to Natera's 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-13 01:51:02 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-12 21:31:26 |
Czytaj oryginał (ang.) |
| Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates |
Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago. |
zacks.com |
2024-11-12 21:00:43 |
Czytaj oryginał (ang.) |
| 3 Under-the-Radar Healthcare Companies |
The healthcare sector is vast and includes everything from massive legacy companies including UnitedHealth Group Inc. NYSE: UNH and McKesson Corp. NYSE: MCK to tiny upstart pharmaceuticals firms. Investors looking to explore this sector thus have a choice about whether to focus on established companies with steadier business operations but, perhaps, less of a possibility of future growth, or on smaller firms that offer a higher-risk, higher-reward prospect. |
marketbeat.com |
2024-11-11 10:01:45 |
Czytaj oryginał (ang.) |
| Natera to Participate in Upcoming Investor Conferences |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December. The UBS Global Healthcare Conference on Thursday, Nov. 14 at 11:00 am ET | 8:00 am PT in Rancho Palos Verdes, CA. The Wolfe Research Healthcare Conference on Tuesday, Nov. 19 at 11:00 am ET | 8:00 am PT in New York, NY. The 36th Annual Piper Sandler Healt. |
businesswire.com |
2024-11-08 11:00:00 |
Czytaj oryginał (ang.) |
| Natera to Report its Third Quarter 2024 Results on November 12, 2024 |
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Third Quarter 2024 Financial Results Date: Tuesday, Nov. 1. |
businesswire.com |
2024-11-01 11:00:00 |
Czytaj oryginał (ang.) |
| Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds |
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Holdings Corp. have outperformed the market and beaten analysts expectations. Natera's oncology tests driving revenue growth and GeneDx focusing on newborn rare disease diagnostics. Both firms have been improving financial metrics, with Natera showing strong revenue growth driven by oncology tests in Q2 2024, while GeneDx achieved profitability in Q3 2024. |
seekingalpha.com |
2024-10-31 20:11:45 |
Czytaj oryginał (ang.) |
| Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD |
The Cigna Group reported a $739 million third quarter profit despite a $1 billion loss on its investment in clinic operator VillageMD. |
forbes.com |
2024-10-31 08:00:00 |
Czytaj oryginał (ang.) |